NucleoDry: Development of a platform for dry mRNA vaccines and lipid nanoformulations
| Reference number | |
| Coordinator | RISE Research Institutes of Sweden AB - Biovetenskap och hälsa |
| Funding from Vinnova | SEK 4 994 980 |
| Project duration | February 2022 - June 2025 |
| Status | Completed |
| Venture | Next-Generation Biologics 5 |
| Call | New and improved biological drugs in healthcare |
Important results from the project
NucleoDry developed a process for mRNA-LNP products that remain stable at room temperature, and investigated how manufacturing and storage affect efficacy. The focus was on cost-effective, patent-free lipids and durable dry vaccines. An in vivo mouse study showed promising results for a dry LNP vaccine stored at room temperature. In addition to scientific progress, NucleoDry has strengthened Swedish drug development through collaboration between academia, research institutes, and industry.
Expected long term effects
NucleoDry has established collaboration among its partners as well as with external academia, and industry, forming a vaccine development network. This collaboration has led to more clinically relevant studies and innovations, enabling accelerated development of gene therapies in Sweden. Together with other contacts and partnerships, the project partners have applied for funding to continue research and product development. One approved initiative is a joint PhD project on vaccine stability.
Approach and implementation
The project was led by a steering group responsible for progress, reporting, planning, and risk management. A WP coordination group facilitated collaboration across partners, evaluated outcomes, and proposed actions. This group reported to the steering group, which made decisions on adjustments to the project timeline and direction. The structure enabled proactive timeline adjustments. Effective coordination was key to executing a project spanning multiple sites.